Andreessen Horowitz Funds Sell $7.18M in Nautilus Biotechnology Shares
NAUT has more than doubled off its 52-week low of $0.62.
Summary
Andreessen Horowitz funds sold $7.18 million worth of Nautilus Biotechnology shares, significantly reducing their stake by over 28% of their prior holdings.
Key Events · Ownership and Investor Activity · NAUT
-
Significant Share Sale
Andreessen Horowitz funds and co-founders sold 3,590,863 shares of common stock on June 26, 2026, at $2.00 per share.
-
Total Transaction Value
The sale generated approximately $7.18 million in proceeds.
-
Reduced Ownership Stake
This transaction reduces their beneficial ownership to 9,063,054 shares, representing 7.1% of the outstanding common stock. This sale represents over 28% of their prior holdings.
-
Follows Previous Divestment
This sale follows a previous divestment of 5 million shares by Andreessen Horowitz funds reported in a Schedule 13D/A filing on June 4, 2026.
Analysis · NAUT · Industrial Applications And Services
Andreessen Horowitz funds and co-founders Marc Andreessen and Benjamin Horowitz have significantly reduced their stake in Nautilus Biotechnology by selling over 3.59 million shares for $7.18 million. This marks a substantial reduction in their holdings, representing over 28% of their previous position, and follows a prior sale of 5 million shares in early June. This continued divestment by a major institutional investor could signal a loss of conviction or a strategic portfolio rebalancing.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAUT was trading at $1.87 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $237.6M. The 52-week trading range was $0.62 to $4.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.